MBRX— Moleculin Biotech, Inc.

Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Moleculin Biotech secures $8.3M from warrant exercises, issues new 5-year warrants

Moleculin announces exercise of warrants for $6.8M

Moleculin to execute 1-for-25 reverse stock split